STOCK TITAN
  1. Home
  2. News
  3. INKT

Mink Therapeutics, Inc. - INKT STOCK NEWS

Welcome to our dedicated page for Mink Therapeutics news (Ticker: INKT), a resource for investors and traders seeking the latest updates and insights on Mink Therapeutics stock.

MiNK Therapeutics, Inc. (INKT) is a clinical-stage biopharmaceutical company pioneering allogeneic iNKT cell therapies for cancer and immune-mediated diseases. This page provides investors and industry observers with timely updates on material developments, including clinical trial progress, regulatory milestones, and strategic partnerships.

Access verified press releases and news articles covering MiNK Therapeutics' innovative pipeline, manufacturing advancements, and collaborative research initiatives. Content spans earnings announcements, trial data disclosures, executive leadership updates, and scientific presentations relevant to the company’s position in the immunotherapy sector.

Bookmark this page for streamlined tracking of INKT’s progress in developing off-the-shelf cellular therapies. Check regularly for authoritative updates that inform analysis of the company’s scientific and commercial trajectory.

News

MiNK Therapeutics Presents Clinical Activity and Long-Term Persistence of Allogeneic iNKT Cells in Solid Tumors at SITC 2023

Rhea-AI Summary
MiNK Therapeutics, Inc. presented new data on their allogeneic cell therapy, agenT-797, at the Society for Immunotherapy of Cancer's Annual Meeting. The therapy showed clinical benefit in heavily pre-treated patients with solid tumors, including long-term disease stabilization and tolerable safety profile. AgenT-797 demonstrated long-term persistence and induced a potent anti-tumor response. Expansion of clinical programs is underway in additional solid tumor settings, and a randomized phase 2 trial in gastric cancer is expected to launch by year-end 2023.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
13.59%
Tags
none
-
News

MiNK to Provide Third Quarter 2023 Financial Report and Corporate Update

Rhea-AI Summary
MiNK Therapeutics, Inc. (NASDAQ: INKT) will release its third quarter 2023 financial results on Nov. 9, 2023.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
7.57%
Tags
earnings
-
News

MiNK Therapeutics To Present Data Update From Allogeneic iNKT Cells in Solid Tumors at SITC 2023

Rhea-AI Summary
MiNK Therapeutics (NASDAQ: INKT) plans to unveil updated clinical and translational data on agenT-797's mechanism of action in solid tumors at the SITC Annual Meeting.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.38%
Tags
conferences
News

MiNK Therapeutics to Participate in September Investor Conferences

Rhea-AI Summary
MiNK Therapeutics (Nasdaq: INKT) announces CEO participation in investor conferences
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-8.24%
Tags
conferences
-
News

MiNK Therapeutics Reports Second Quarter 2023 Results

Rhea-AI Summary
MiNK Therapeutics, Inc. (INKT) reported significant clinical progress with agenT-797, an allogeneic iNKT therapy, showing persistence and clinical benefit in patients with solid tumor cancers. The company announced a planned launch of a randomized Phase 2 trial in 2L gastric cancer, as well as progress on a novel FAP-CAR-iNKT cell therapy, MiNK-215, that eliminated tumors in NSCLC models. Financial results indicated a cash balance of $10.6 million at the end of the second quarter 2023, with a net loss of $11.9 million for the first six months of the year.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
6.67%
Tags
earnings
-
News

MiNK to Provide Second Quarter 2023 Financial Report and Corporate Update

Rhea-AI Summary
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
3.59%
Tags
earnings
News

MiNK Therapeutics Announces Virtual Annual Shareholders Meeting

Rhea-AI Summary
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.55%
Tags
none
-
News

MiNK Presents Clinical Data on Allogeneic iNKT Cells (agenT-797) in Severe Respiratory Distress at the American Thoracic Society International Conference

Rhea-AI Summary
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
16.85%
Tags
clinical trial
-
News

MiNK's Novel FAP-CAR-iNKT Presented at ASGCT

Rhea-AI Summary
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-4.44%
Tags
none
News

MiNK Therapeutics Reports Corporate Update and First Quarter 2023 Financial Results

Rhea-AI Summary
MiNK Therapeutics, Inc. provided a corporate update and reported financial results for the first quarter 2023. Their lead program, agenT-797, showed promising results in advanced solid cancers and they have launched expansion studies in NSCLC and gastric cancer. They also announced the development of a novel FAP-CAR-iNKT therapy. MiNK will present new data on their allogeneic FAP-CAR-iNKT program at the ASGCT Annual Meeting. They ended the first quarter with a cash balance of $14.9 million.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
7.28%
Tags
earnings
Stock INKT logo
Mink Therapeutics, Inc.

Nasdaq:INKT

INKT Rankings

N/A Ranked by Market Cap
N/A Ranked by Dividends

INKT Stock Data

28.76M
1.00M
74.83%
2.09%
0.68%
Biotechnology
Biological Products, (no Disgnostic Substances)
Link
United States
NEW YORK